Ishihama H, Suzuki Y, Muramatsu K, Nagai M, Kokubo M, Shiraya H, Kawakita A, Nishimura Y, Imamura T, Kobayashi M
Department of Paediatrics, Toyohashi Municipal Hospital, Aichi, Japan.
Arch Dis Child. 1994 Aug;71(2):144-6. doi: 10.1136/adc.71.2.144.
Insulin-like growth factor I (IGF-I) is a useful therapeutic agent in insulin resistant diabetes mellitus due to insulin receptor disease because of its hypoglycaemic effects through the IGF-I receptor. A girl with typical type A insulin resistant syndrome was treated with IGF-I for two years and the treatment was effective in ameliorating hyperglycaemia. Overproduction of testosterone in polycystic ovaries was aggravated with this treatment, however. Therefore, IGF-I treatment may be used for glycaemic control but with caution because of its possible side effect of aggravating hyperandrogenism in these patients.
胰岛素样生长因子I(IGF-I)是治疗因胰岛素受体疾病导致的胰岛素抵抗型糖尿病的一种有效治疗药物,因为它通过IGF-I受体发挥降血糖作用。一名患有典型A型胰岛素抵抗综合征的女孩接受了IGF-I治疗两年,该治疗在改善高血糖方面有效。然而,这种治疗使多囊卵巢中睾酮的过度分泌加剧。因此,IGF-I治疗可用于控制血糖,但由于其可能加重这些患者高雄激素血症的副作用,使用时需谨慎。